Digital Pathology & Imaging - software & AI news

Daily news on software, AI, and companies shaping digital pathology & imaging.

Showing 301 results
Press release cover image

Oct 19, 2026

HISTOINDEX AND A*STAR PARTNER TO ADVANCE EARLY-STAGE DEVELOPMENT OF PIPELINE THERAPIES FOR FIBROTIC DISEASES

SINGAPORE, Oct. 18, 2026 /PRNewswire/ -- HistoIndex, a pioneer in AI-driven digital pathology for fibrotic diseases, and the Agency for Science, Technology and Research (A*STAR), Singapore's lead public sector R&D agency, have signed a Memorandum of Understanding (MoU) to collaborate on the preclinical evaluation and characterization of therapeutic candidates for various fibrotic diseases, including cancer-associated fibrosis.The partnership will bring together A*STAR's scientific expertise
Press release cover image

Oct 19, 2026

HISTOINDEX AND A*STAR PARTNER TO ADVANCE EARLY-STAGE DEVELOPMENT OF PIPELINE THERAPIES FOR FIBROTIC DISEASES

SINGAPORE, Oct. 18, 2026 /PRNewswire/ -- HistoIndex, a pioneer in AI-driven digital pathology for fibrotic diseases, and the Agency for Science, Technology and Research (A*STAR), Singapore's lead public sector R&D agency, have signed a Memorandum of Understanding (MoU) to collaborate on the preclinical evaluation and characterization of therapeutic candidates for various fibrotic diseases, including cancer-associated fibrosis.Continue Reading The partnership will bring toget
MRI machine in a clinical imaging room

Oct 19, 2026

Siemens Healthineers partners with Paradromics to build out new imaging system to support BCIs

Siemens Healthineers and Paradromics have announced a partnership to develop an advanced multimodal imaging platform aimed at enhancing the clinical application of brain-computer interfaces (BCIs).This collaboration seeks to merge Siemens Healthineers' expertise in medical imaging with Paradromics' knowledge in BCI technology. The goal is to create an integrated imaging solution that covers various aspects of BCI care, including assessing patient eligibility, identifying neural targets, planning
Press release cover image

Oct 16, 2026

Nanox AI Ltd. Enters into Distribution Agreement with Technologic s.r.l., an Affiliate of Tecnologie Avanzate, to Commercialize Nanox.AI Bone Solution in Italy

Agreement aims to expand the commercial reach of Nanox.AI's Bone Solution in the Italian healthcare market. Collaboration leverages Tecnologie Avanzate's 50 years of experience in the Italian medical technology market, established healthcare industry relationships, and expertise in introducing advanced medical technologies. PETACH TIKVA, Israel, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Nano-X Imaging Ltd. (NASDAQ: NNOX) ("Nanox" or the "Company"), a leader in innovative medical imaging technology, to
Press release cover image

Oct 16, 2026

Aignostics Launches HETA Clinical, a New Family of AI Products that Speed Up Pathology Workflows and Reduce Failed Molecular Tests

BERLIN and NEW YORK, Oct. 16, 2026 /PRNewswire/ -- Today, Aignostics announced the launch of HETA Clinical, a new family of pan-cancer AI products spanning the pathology workflow from intake and evaluation to molecular testing. The first four HETA Clinical products measure slide quality, tumor presence, mitotic counts and tumor cellularity across whole slide H&E images.HETA Quality Control measures slide quality before analysis, identifying a range of slide quality issues.HETA Tumor Detect a
Press release cover image

Oct 15, 2026

ELEPHAS PUBLISHES PEER-REVIEWED DATA IN CELL REPORTS MEDICINE DEMONSTRATING elive™ PLATFORM'S IMMUNOTHERAPY RESPONSE MEASUREMENT

Study Demonstrates 93% Accuracy in Predicting Clinical Benefit and Highlights the Platform's Potential to Enhance Clinical Decision Making MADISON, Wis., Oct. 15, 2026 /PRNewswire/ -- Elephas Biosciences Corporation, a private company that has developed an innovative live tissue platform for immunotherapy response prediction, announced today the publication of peer-reviewed data in Cell Reports Medicine evaluating the predictive performance of its elive platform. The study evaluated live tumor f
Press release cover image

Oct 15, 2026

SimBioSys Secures FDA Clearance for TumorSight® Risk, Introducing the World's First AI-Powered, MRI-Derived Breast Cancer Recurrence Risk Assessment

Novel software transforms routinely collected MRI, pathology and clinical data into personalized five- and ten-year recurrence risk insight for women with early-stage breast cancerCHICAGO, Oct. 15, 2026 /PRNewswire/ -- SimBioSys®, an AI-driven precision medicine company revolutionizing how cancer is understood and treated, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of TumorSight® Risk, the world's first AI-powered, MRI-derived prognostic tool for assessing breast ca
Press release cover image

Oct 15, 2026

BeSound Opens NYC Flagship to Rebuild Breast Screening Around Ultrasound

The women-founded company is bringing FDA-approved 3D automated breast ultrasound to Manhattan, pairing a pain-free, radiation-free scan with an AI layer that aims to get smarter with every examNEW YORK, Oct. 15, 2026 /PRNewswire/ -- BeSound, a next-generation breast imaging platform modernizing cancer screening with FDA-approved 3D ultrasound, today opened its NYC flagship location in Flatiron as it lays the groundwork to scale nationally. Women can book online in minutes with no referral, get
Press release cover image

Oct 14, 2026

Lunit SCOPE Reveals HER2 Expression Differences Linked to Treatment Response Beyond Conventional Testing in Nature Medicine Study

AI-powered whole-slide analysis provides insights into treatment response beyond conventional HER2 classificationSEOUL, South Korea, Oct. 14, 2026 /PRNewswire/ -- Lunit (KRX: 328130), a leading provider of AI for cancer diagnostics and precision oncology, today announced findings from a study published in Nature Medicine, in which its AI-powered pathology platform, Lunit SCOPE, identified an association between quantitative HER2 expression and treatment response in patients with HER2-positive ad
Press release cover image

Oct 14, 2026

Brainomix and Pulmonary Fibrosis Foundation Partner to Bring Patient Perspectives to AI-Powered Pulmonary Fibrosis Care

New multi-phase patient engagement initiative will explore how AI-powered CT analysis can help people living with pulmonary fibrosis better understand their disease and support shared treatment decisionsOXFORD, England and CHICAGO, Oct. 14, 2026 /PRNewswire/ -- Brainomix, a leading medtech company specializing in AI-powered imaging tools for lung disease and stroke, today announced a new partnership with the Pulmonary Fibrosis Foundation (PFF) to bring the voices of patients and caregivers into
A minimalist illustration of a pathology slide and microscope in a dark color scheme.

Oct 14, 2026

Agilent spends $240M upfront to buy digital pathology specialist Proscia

Agilent Technologies has announced its acquisition of digital pathology firm Proscia for $240 million, with potential additional payments based on future performance.This acquisition grants Agilent access to Proscia's Concentriq software platform, which serves as a pivotal tool for digital pathology, aiding clinical and life sciences entities in the U.S. and Europe. The platform is currently utilized by over 4,000 laboratories, hospitals, and pharmaceutical companies to streamline the management
Press release cover image

Oct 13, 2026

Spectral AI’s DeepView™ System Showcased at the 2026 American College of Emergency Physicians (ACEP) Scientific Assembly

DALLAS, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today highlighted its participation at the 2026 American College of Emergency Physicians (ACEP) Scientific Assembly, held October 5-8 in Chicago, IL.  The Company showcased its FDA-cleared DeepView™ System for Burn Indication at this year’s Assembly. Wid